NeoGenomics, Inc. reported Q4 2025 consolidated revenue of $190 million, up 11% from Q4 2024, and full year 2025 revenue of $727 million, up 10% from 2024. The company issued 2026 guidance for revenue of $793-$801 million and adjusted EBITDA of $55-$57 million.
Key takeaways
Q4 2025 revenue $190 million, +11% vs Q4 2024
Full year 2025 revenue $727 million, +10% vs 2024
Q4 2025 net loss $10 million, -36% vs Q4 2024 $15 million
Full year 2025 net loss $108 million, +37% vs 2024 $79 million
Q4 adjusted EBITDA $13 million, +13% vs Q4 2024 $12 million
2026 guidance: revenue $793-801 million (+9-10%), adjusted EBITDA $55-57 million (+27-31%)